Key terms

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CLDX news

Mar 21 10:46am ET Cantor Fitzgerald biotech analysts to hold analyst/industry conference call Mar 01 12:57am ET Celldex Gains Buy Rating Amid Strong Barzolvolimab Phase 2 Results and Promising Clinical Timelines Feb 29 9:45pm ET Celldex 8.52M share Secondary priced at $47.00 Feb 28 5:24pm ET Celldex announces $250M offering of common stock Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 27 11:40pm ET Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH) Feb 27 8:30am ET Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Revolution Medicines (RVMD) Feb 27 7:51am ET Celldex price target raised to $90 from $72 at Guggenheim Feb 27 1:04am ET Celldex Therapeutics’ New Regulation Risk – A Cause for Worry? Feb 26 7:55am ET Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX) Feb 26 7:36am ET TD Cowen Keeps Their Buy Rating on Celldex (CLDX) Feb 26 7:07am ET Celldex expects cash to fund operations into 2026 Feb 26 7:06am ET Celldex reports Q4 EPS (83c), consensus (74c) Feb 26 6:30am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Abbott Labs (ABT) and Morphic Holding (MORF) Feb 26 6:20am ET Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), Legend Biotech (LEGN) and Celldex (CLDX) Feb 25 6:32am ET Celldex presents 12-week results from Barzolvolimab Phase 2 study in CSU Feb 23 11:04am ET Biotech Alert: Searches spiking for these stocks today Feb 22 10:59am ET Biotech Alert: Searches spiking for these stocks today Feb 20 5:26am ET TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels Feb 07 8:36am ET Buy Rating Affirmed for Celldex Amid Promising Barzovolimab Data for Chronic Spontaneous Urticaria Feb 07 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 05 8:20am ET Celldex announces upcoming presentation of barzolvolimab Phase 2 results Jan 31 5:49am ET Analyst Maintains Hold Rating on Celldex Amid Anticipated Phase 2 Results and Safety Considerations

No recent news articles are available for CLDX

No recent press releases are available for CLDX

CLDX Financials

1-year income & revenue

Key terms

CLDX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CLDX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms